

REMARKS

Claims 41-44, 52, 55 and 56 were examined in the Office Action under reply. Claims 41-44, 52 and 55 were allowed. New claim 58 has been added and finds support, for example, in original claim 35 and page 14, lines 2-4. Claim 56 has been canceled, without prejudice or disclaimer. Thus, claims 41-44, 52, 55 and 58 are pending as shown above.


Claim 56 was rejected under 35 U.S.C. §112, first paragraph as failing to comply with the written description requirement. Although applicants believe claim 56 to be adequately supported, the claim is being canceled solely in an effort to advance prosecution. Thus, this basis for rejection has been overcome and withdrawal thereof is respectfully requested. Applicants reserve the right to file one or more continuing applications directed to the subject matter of any of the canceled claims.

Accordingly, applicants respectfully submit that the application is now in condition for allowance.

Please direct all further communications in this application to:

Michael J. Moran
Novartis Vaccines & Diagnostics, Inc.
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2969
Facsimile: (510) 655-3542

Respectfully submitted,



Dahna S. Pasternak
Reg. No. 41,411
Attorney for Applicants

Dated: August 21, 2006 By:

Novartis Vaccines & Diagnostics, Inc.
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097